Inventiva S.A.

Paris Stock Exchange IVA.PA

Inventiva S.A. Total Non-Current Liabilities for the year ending December 31, 2023: USD 56.77 M

Inventiva S.A. Total Non-Current Liabilities is USD 56.77 M for the year ending December 31, 2023, a 33.22% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Inventiva S.A. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 42.61 M, a 264.67% change year over year.
Inventiva S.A. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 11.69 M, a -30.68% change year over year.
Inventiva S.A. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 16.86 M, a 782.07% change year over year.
Inventiva S.A. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 1.91 M, a -46.72% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Paris Stock Exchange: IVA.PA

Inventiva S.A.

CEO	Mr. Frederic Cren
IPO Date	Feb. 15, 2017
Location	France
Headquarters	50 rue de Dijon
Employees	123
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Composite Materials Pet Food Pharmaceuticals Plastics Vaccines

Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Key trends

Past 5 years